Investors pinpoint 3 promising signs for imaging startup Nanox

Nanox Imaging has faced a number of negative claims in recent months, including a class action lawsuit alleging the startup has misled investors. But a recent piece published by the Motley Fool identified three "green flags" that may indicate a brighter future for the firm.

For one, the Nanox.ARC system has cost advantages over traditional machines, including no internal filament that burns out and needs replacing like conventional modalities, according to the investing news site. Its flagship product is smaller and requires less energy than normal x-ray systems. Nanox expects is x-ray tube to cost $100 per unit, compared to the up to $150,000 required today.

Motley Fool contributor Alex Carchidi writes that the company expects to receive regulatory approval for its Nanox.ARC in the first quarter of 2021. And the startup has more than 5,150 preorders for this unit, according to the Oct. 26 report, with expectations to have installed 15,000 machines by 2024.

Perhaps the largest selling point, however, is the Israeli startup’s pay-per-scan pricing model that accompanies its minimum annual service fee. “This could drive down the cost of individual scans to as low as $14 per scan while also keeping up-front capital expenditures low,” Carchidi writes.

Of course, Nanox has not yet proven that its imaging system works, but the company said it plans to demonstrate its technology at RSNA in December.

Read more from the Motley Fool below.

""

Matt joined Chicago’s TriMed team in 2018 covering all areas of health imaging after two years reporting on the hospital field. He holds a bachelor’s in English from UIC, and enjoys a good cup of coffee and an interesting documentary.

Around the web

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care. 

After three years of intermittent shortages of nuclear imaging tracer technetium-99m pyrophosphate, there are no signs of the shortage abating.